Literature DB >> 21793074

Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.

K R Keshari1, H Tsachres, R Iman, L Delos Santos, Z L Tabatabai, K Shinohara, D B Vigneron, J Kurhanewicz.   

Abstract

This study investigates the relationship between phospholipid metabolite concentrations, Gleason score, rate of cellular proliferation and surgical stage in malignant prostatectomy samples by performing one- and two-dimensional, high-resolution magic angle spinning, total correlation spectroscopy, pathology and Ki-67 staining on the same surgical samples. At radical prostatectomy, surgical samples were obtained from 49 patients [41 with localized TNM stage T1 and T2, and eight with local cancer spread (TNM stage T3)]. Thirteen of the tissue samples were high-grade prostate cancer [Gleason score: 4 + 3 (n = 7); 4 + 4 (n = 6)], 22 low-grade prostate cancer [Gleason score: 3 + 3 (n = 17); 3 + 4 (n = 5)] and 14 benign prostate tissues. This study demonstrates that high-grade prostate cancer shows significantly higher Ki-67 staining and concentrations of phosphocholine (PC) and glycerophosphocholine (GPC) than does low-grade prostate cancer (2.4 ± 2.8% versus 7.6 ± 3.5%, p < 0.005, and 0.671 ± 0.461 versus 1.87 ± 2.15 mmolal, p < 0.005, respectively). In patients with local cancer spread, increases in [PC + GPC + PE + GPE] (PE, phosphoethanolamine; GPE, glycerophosphoethanolamine] and Ki-67 index approached significance (4.2 ± 2.5 versus 2.7 ± 2.4 mmolal, p = 0.07, and 5.3 ± 3.8% versus 2.9 ± 3.8%, p = 0.07, respectively). PC and Ki-67 were significantly lower and GPC higher in prostate tissues when compared with cell cultures, presumably because of a lack of important stromal-epithelial interactions in cell cultures. The findings of this study will need to be validated in a larger cohort of surgical patients with clinical outcome data, but support the role of in vivo (1)H MRSI in discriminating between low- and high-grade prostate cancer based on the magnitude of elevation of the in vivo total choline resonance.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793074      PMCID: PMC3653775          DOI: 10.1002/nbm.1738

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  49 in total

1.  Ki-67 expression in early prostate cancer and associated pathological lesions.

Authors:  M R Feneley; M P Young; C Chinyama; R S Kirby; M C Parkinson
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

2.  Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis.

Authors:  K K Yu; H Hricak; R Alagappan; D M Chernoff; P Bacchetti; C J Zaloudek
Journal:  Radiology       Date:  1997-03       Impact factor: 11.105

3.  Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.

Authors:  Mark G Swanson; Andrew S Zektzer; Z Laura Tabatabai; Jeffry Simko; Samson Jarso; Kayvan R Keshari; Lars Schmitt; Peter R Carroll; Katsuto Shinohara; Daniel B Vigneron; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2006-06       Impact factor: 4.668

Review 4.  Histologic grading of prostate cancer: a perspective.

Authors:  D F Gleason
Journal:  Hum Pathol       Date:  1992-03       Impact factor: 3.466

5.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.

Authors:  K K Yu; J Scheidler; H Hricak; D B Vigneron; C J Zaloudek; R G Males; S J Nelson; P R Carroll; J Kurhanewicz
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

6.  High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies.

Authors:  Jack J A van Asten; Vincent Cuijpers; Christina Hulsbergen-van de Kaa; Claudia Soede-Huijbregts; J Alfred Witjes; Albert Verhofstad; Arend Heerschap
Journal:  MAGMA       Date:  2008-11-25       Impact factor: 2.310

7.  Predicting quality of life after radical prostatectomy: results from CaPSURE.

Authors:  Jim C Hu; Eric P Elkin; David J Pasta; Deborah P Lubeck; Michael W Kattan; Peter R Carroll; Mark S Litwin
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

8.  Phospholipid metabolites, prognosis and proliferation in human breast carcinoma.

Authors:  T A Smith; C Bush; C Jameson; J C Titley; M O Leach; D E Wilman; V R McCready
Journal:  NMR Biomed       Date:  1993 Sep-Oct       Impact factor: 4.044

9.  Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.

Authors:  WeiDe Zhong; Jinyu Peng; HuiChan He; Dinglan Wu; ZhaoDong Han; XueCheng Bi; QiShan Dai
Journal:  Clin Invest Med       Date:  2008       Impact factor: 0.825

10.  Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study.

Authors:  J Kurhanewicz; R Dahiya; J M Macdonald; L H Chang; T L James; P Narayan
Journal:  Magn Reson Med       Date:  1993-02       Impact factor: 4.668

View more
  27 in total

Review 1.  Novel Approaches to Imaging Tumor Metabolism.

Authors:  Sui-Seng Tee; Kayvan R Keshari
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

Review 2.  NMR-based metabolomics studies of human prostate cancer tissue.

Authors:  Ana Rita Lima; Joana Pinto; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho
Journal:  Metabolomics       Date:  2018-06-18       Impact factor: 4.290

3.  Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer.

Authors:  Roopa Thapar; Mark A Titus
Journal:  Curr Metabolomics       Date:  2014-04

4.  The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism.

Authors:  Prakash Chinnaiyan; Elizabeth Kensicki; Gregory Bloom; Antony Prabhu; Bhaswati Sarcar; Soumen Kahali; Steven Eschrich; Xiaotao Qu; Peter Forsyth; Robert Gillies
Journal:  Cancer Res       Date:  2012-10-01       Impact factor: 12.701

5.  Dietary choline and betaine intakes and risk of total and lethal prostate cancer in the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Peijin Han; Aurelian Bidulescu; John R Barber; Steven H Zeisel; Corinne E Joshu; Anna E Prizment; Mara Z Vitolins; Elizabeth A Platz
Journal:  Cancer Causes Control       Date:  2019-03-01       Impact factor: 2.506

6.  Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.

Authors:  Kayvan R Keshari; Renuka Sriram; Mark Van Criekinge; David M Wilson; Zhen J Wang; Daniel B Vigneron; Donna M Peehl; John Kurhanewicz
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104

Review 7.  High-resolution magic angle spinning 1H MRS in prostate cancer.

Authors:  Emily A Decelle; Leo L Cheng
Journal:  NMR Biomed       Date:  2013-03-26       Impact factor: 4.044

Review 8.  Chemistry and biochemistry of 13C hyperpolarized magnetic resonance using dynamic nuclear polarization.

Authors:  Kayvan R Keshari; David M Wilson
Journal:  Chem Soc Rev       Date:  2013-12-20       Impact factor: 54.564

9.  (31)P CSI of the human brain in healthy subjects and tumor patients at 9.4 T with a three-layered multi-nuclear coil: initial results.

Authors:  Christian Mirkes; Gunamony Shajan; Grzegorz Chadzynski; Kai Buckenmaier; Benjamin Bender; Klaus Scheffler
Journal:  MAGMA       Date:  2016-01-25       Impact factor: 2.310

10.  Choline intake and risk of lethal prostate cancer: incidence and survival.

Authors:  Erin L Richman; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci; Steven H Zeisel; Walter C Willett; June M Chan
Journal:  Am J Clin Nutr       Date:  2012-09-05       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.